{"id":42189,"date":"2019-08-28T08:02:55","date_gmt":"2019-08-28T12:02:55","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=42189"},"modified":"2019-08-28T01:47:40","modified_gmt":"2019-08-28T05:47:40","slug":"amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189","title":{"rendered":"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG)"},"content":{"rendered":"<p><strong>Amgen Inc. (NASDAQ:AMGN)<\/strong> has announced the purchase of <strong>Celgene Corporation\u2019s (NASDAQ:CELG)<\/strong> leading immunology drug Otezla for around <a href=\"https:\/\/articles2.marketrealist.com\/2019\/08\/amgen-celgenes-otezla-deal-key-highlights\/\">$13.4 billion<\/a>.<\/p>\n<h2><strong>Otezla purchase deal to be finalized at the end of the year <\/strong><\/h2>\n<p>The company has indicated that the deal will be closed at the end of the year. Following the announcement, Amgen\u2019s stock gained 2.85% to close the session at <a href=\"https:\/\/www.techinvestornews.com\/Mobile\/Latest-Mobile-News\/amgen-and-celgenes-otezla-deal-key-highlights\" target=\"_blank\" rel=\"noopener noreferrer\">$204.75<\/a>. The gain in stock despite the amount offered for Otezla being a huge sum demonstrates investor optimism for the move.<\/p>\n<p>Amgen has already cemented its foothold in the immunology space with its drug, Enbrel. Equally, the company has launched Amgevita in some European markets. Amgevita is biologically similar to <strong>AbbVie Inc.\u2019s (NYSE:ABBV)<\/strong> Humira. Investors are optimistic that the company will leverage its potential in the immunology space to advance the revenue trajectory for Otezla.<\/p>\n<p>Investors are, however, wary about the possibility of a deal between Amgen and <strong>Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)<\/strong>. This is because Amgen committed a significant amount of money to acquire Otezla, which has made the possibility of another big deal unlikely.<\/p>\n<h2><strong>Otezla to boost Amgen revenues<\/strong><\/h2>\n<p>The purchase of Otezla will be accretive to the company\u2019s revenues as well as non-GAAP EPS immediately after finalizing the deal. Otezla is expected to generate revenues of around <a href=\"https:\/\/www.archyde.com\/business\/the-otezla-agreement-of-amgen-and-celgene-key-aspects\/\" target=\"_blank\" rel=\"noopener noreferrer\">$1.9 billion<\/a> this year. The company has predicted two double-digit YoY sales growth for the drug until 2024.<\/p>\n<p>The drug will also strengthen the company\u2019s market position in the US as well as internationally. So far the drug has received approval from the FDA for three indications and has already been approved in 54 countries.<\/p>\n<p>The sale of Otezla by Celgene is of massive significance to the completion of a merger between Celgene and <strong>Bristol-Myers Squibb Co. (NYSE:BMY)<\/strong>. The megamerger that was announced at the beginning of the year and in April, both companies shareholders approved the move. \u00a0However, in June Bristol-Myers Squibb reviewed the timeline of the completion of the merger to late 2019 or early 2020.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amgen Inc. (NASDAQ:AMGN) has announced the purchase of Celgene Corporation\u2019s (NASDAQ:CELG) leading immunology drug Otezla for around $13.4 billion. Otezla purchase deal to be finalized [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":42190,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[7095,2831,13931,13930,1520,2861],"stock_ticker":[13929],"class_list":["post-42189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-amgen-inc","tag-amgen-inc-nasdaqamgn","tag-celgene-corporations","tag-celgene-corporations-nasdaqcelg","tag-nasdaqamgn","tag-nasdaqcelg","stock_ticker-amgn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Amgen Inc. (NASDAQ:AMGN) has announced the purchase of Celgene Corporation\u2019s (NASDAQ:CELG) leading immunology drug Otezla for around $13.4 billion. Otezla purchase deal to be finalized [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-08-28T12:02:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"413\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG)\",\"datePublished\":\"2019-08-28T12:02:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189\"},\"wordCount\":344,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg\",\"keywords\":[\"Amgen Inc.\",\"Amgen Inc. (NASDAQ:AMGN)\",\"Celgene Corporation\u2019s\",\"Celgene Corporation\u2019s (NASDAQ:CELG)\",\"NASDAQ:AMGN\",\"NASDAQ:CELG\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189\",\"name\":\"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg\",\"datePublished\":\"2019-08-28T12:02:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg\",\"width\":620,\"height\":413},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189","og_locale":"en_US","og_type":"article","og_title":"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG) - Wall Street PR","og_description":"Amgen Inc. (NASDAQ:AMGN) has announced the purchase of Celgene Corporation\u2019s (NASDAQ:CELG) leading immunology drug Otezla for around $13.4 billion. Otezla purchase deal to be finalized [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2019-08-28T12:02:55+00:00","og_image":[{"width":620,"height":413,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG)","datePublished":"2019-08-28T12:02:55+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189"},"wordCount":344,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg","keywords":["Amgen Inc.","Amgen Inc. (NASDAQ:AMGN)","Celgene Corporation\u2019s","Celgene Corporation\u2019s (NASDAQ:CELG)","NASDAQ:AMGN","NASDAQ:CELG"],"articleSection":["Health"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189","url":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189","name":"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg","datePublished":"2019-08-28T12:02:55+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/08\/Amgen.jpg","width":620,"height":413},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-announces-the-purchase-of-immunology-drug-otezla-from-celgene-corporation-nasdaqcelg-42189#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Amgen Inc. (NASDAQ:AMGN) Announces The Purchase of Immunology Drug Otezla from Celgene Corporation (NASDAQ:CELG)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/42189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=42189"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/42189\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/42190"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=42189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=42189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=42189"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=42189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}